Sommaire

• • ·Recombinant humanised anti-PD-1 monoclonal antibody (JS001) treatment for patients with refractory or metastatic nasopharyngeal carcinoma: preliminary results of an open-label, phase 1b/2, clinical study

    Page :S1

    Ruihua Xu, Fenghua Wang, Qi Li, Jianhua Shi, Lin Shen, Qingyuan Zhang, Xianglin Yuan, Yi Jiang, Nong Xu, Ye Chen, Xichun Hu, Xiaoyan Lin, Shujun Yang, Chao Ren

    Résumé Résumé  
• • ·Comparison between sublobar resection and lobectomy for the surgical treatment of elderly patients with early stage non-small-cell lung cancer (STEPS): an open label, multicentre, non-inferiority, randomised, phase 3 clinical trial

    Page :S2

    Fan Yang, Xizhao Sui, Xiuyuan Chen, Jun Wang

    Résumé Résumé  
• • ·Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study

    Page :S3

    Baohui Han, Kai Li, Qiming Wang, Yizhuo Zhao, Li Zhang, Jianhua Shi, Zhehai Wang, Yin Cheng, Jianxing He, Yuankai Shi, Weiqiang Chen, Xiuwen Wang, Yi Luo, Kejun Nan, Faguang Jin, Baolan Li, Yinlan Chen, Jianying Zhou, Donglin Wang

    Résumé Résumé  
• • ·Concurrent chemoradiotherapy of capecitabine with or without oxaliplatin versus cisplatin with fluorouracil for treatment of squamous oesophageal cancer in Chinese patients (CRTCOESC): an interim report of a randomised, open-label, multicentre trial

    Page :S4

    Ruinuo Jia, Tanyou Shan, Fuyou Zhou, Anping Zheng, Lixin Wan, Zhiqiao Xu, Guobao Zheng, Xiaoyong Luo, Yingjuan Zheng, Yanhui Cui, Guifang Zhang, Dan Zhou, Jiachun Sun, Guoqiang Kong, Xiaozhi Yuan, Ruina Yang, Jing Ren, Wei Wang, Xinshuai Wang, Shegan Gao

    Résumé Résumé  
• • ·Personalised peptide vaccination combined with radiotherapy for patients with advanced hepatocellular carcinoma: a phase 1 study

    Page :S5

    Jie Shen, Zheng-Yun Zou, Li-Feng Wang, Jing Yan, Wei-Wei Kong, Fan-Yan Meng, Fang-Jun Chen, Juan Du, Jie Shao, Qiu-Ping Xu, Ru-Tian Li, Jia Wei, Xiao-Ping Qian, Bao-Rui Liu

    Résumé Résumé  
• • ·Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: a phase 2 trial

    Page :S6

    Xin Wang, Yongyang Yu, Xiangbing Deng, Wenjian Meng, Hong Zhu, Dan Jiang, Hua Zhuang, Bing Wu, Zhiping Li, Meng Qiu, Hongfeng Gou, Feng Bi, Feng Xu, Ziqiang Wang, Zongguang Zhou

    Résumé Résumé  
• • ·Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study

    Page :S7

    Huiping Li, Qingyuan Zhang, Wei Li, Shusen Wang, Ning Liao, Peng Shen, Bin Shao, Wenhui Zhao, Wan Sun, Ping Yan, Diane Wang, Vince (Bai) Li, Carlos Linn, Haihong Shi, Melissa O’Gorman, Binghe Xu

    Résumé Résumé  
• • ·Anti-VEGFR, PDGFR, and CSF1R tyrosine kinase inhibitor CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma: a phase 1 clinical trial

    Page :S8

    Xieqiao Yan, Xinan Sheng, Bixia Tang, Zhihong Chi, Chuanliang Cui, Lu Si, Li Li Mao, Bin Lian, Siming Li, Li Zhou, Xuan Wang, Xue Bai, Yan Kong, Jie Dai, Jun Guo

    Résumé Résumé  
• • ·Chimeric antigen receptor-modified T cells directed against CD19 in patients with relapsed or refractory CD19-positive B-cell lymphomas: interim analysis of a phase 1 study

    Page :S9

    Zhitao Ying, Xiaoyu Xiang, Yuqin Song, Ning Ding, Yufu Lin, Wen Zheng, Xiaopei Wang, Ningjing Lin, Meifeng Tu, Yan Xie, Chen Zhang, Weiping Liu, Lijuan Deng, Yanling Liu, Yunqiang Yue, Xueyun Yu, Hanzhi Liu, Panpan Duan, Mierzhati Mamuti, Xiaokai Guo, Feng Chen, Xiaoyan Wu, Junqing Zhang, Tingting Zhang, Xue F Huang, Lindsey Jones, Xi Kang, Si-Yi Chen, Jun Zhu

    Résumé Résumé  
• • ·Response-adapted therapy for limited stage diffuse large B-cell lymphoma based on interim PET-CT: preliminary results of a phase 2 study

    Page :S10

    Fangfang Lv, Zuguang Xia, Kai Xue, Qunling Zhang, Dongmei Ji, Junning Cao, Xiaonan Hong, Ye Guo

    Résumé Résumé  
• • ·Continuous intravenous infusion of recombinant human endostatin combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer (HELPER): a phase 2, multicentre study

    Page :S11

    Yirui Zhai, Honglian Ma, Zhouguang Hui, Lujun Zhao, Dongming Li, Jun Liang, Xiaozhen Wang, Liming Xu, Bo Chen, Yu Tang, Runye Wu, Yujin Xu, Ming Chen, Luhua Wang

    Résumé Résumé